NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZITUVIO (sitagliptin) by Biocon is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2023.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIO (sitagliptin) is an oral DPP-4 inhibitor approved by the FDA in October 2023 under Biocon sponsorship. It works by inhibiting dipeptidyl peptidase-4 to enhance incretin-mediated glucose control. The drug is indicated for type 2 diabetes management in patients requiring oral antidiabetic therapy.
Growth8.7 years to LOE
Early-stage commercial phase with growth trajectory; brand team likely building field presence and establishing market position in a competitive DPP-4 inhibitor space.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
Started Apr 2026
12 enrolled
Healthy Volunteers
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Semaglutide vs Sitagliptin
Started Oct 2022
58 enrolled
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic Steatohepatitis+1 more
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Started Mar 2022
46 enrolled
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Worked on ZITUVIO at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.